Clinical Research Institute S.C.
Tlalnepantla, Mexico
5 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Bronchiectasis
Boehringer Ingelheim1,755 enrolled494 locationsNCT06872892
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Eli Lilly and Company252 enrolled149 locationsNCT07186101
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Menstrual Migraine
Pfizer723 enrolled122 locationsNCT06641466
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC201 enrolled108 locationsNCT05327114
Recruiting
Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Gastroesophageal Reflux Disease (GERD)
Takeda70 enrolled33 locationsNCT02616302